Mutations leading to ceftolozane/tazobactam and imipenem/cilastatin/relebactam resistance during

 0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Vaughn S Cooper, Glenn J Rapsinski, Alecia B Rokes, Daria Van Tyne

Ngôn ngữ: eng

Ký hiệu phân loại: 995.93 +Solomon Islands

Thông tin xuất bản: United States : Microbiology spectrum , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 54856

UNLABELLED: Identifying resistance mechanisms to novel antimicrobials informs treatment strategies during infection and antimicrobial development. Studying resistance that develops during the treatment of an infection can provide the most clinically relevant mutations conferring resistance, but cross-sectional studies frequently identify multiple candidate resistance mutations without resolving the driver mutation. We performed whole-genome sequencing of longitudinal IMPORTANCE: Antibiotic resistance is a significant challenge for physicians trying to treat infections. The development of novel antibiotics to treat resistant infections has not been prioritized for decades, limiting treatment options for infections caused by many high-priority pathogens. Cross-resistance, when one mutation provides resistance to multiple antibiotics, is most problematic. Mutations that cause cross-resistance need to be considered when developing new antibiotics to guide developers toward drugs with different targets, and thus a better likelihood of efficacy. This work was undertaken to determine the mutation that caused resistance to three antibiotics for highly resistant
Tạo bộ sưu tập với mã QR

THƯ VIỆN - TRƯỜNG ĐẠI HỌC CÔNG NGHỆ TP.HCM

ĐT: (028) 36225755 | Email: tt.thuvien@hutech.edu.vn

Copyright @2024 THƯ VIỆN HUTECH